Soleno Therapeutics INC 8-K filings

Soleno Therapeutics has entered into a five-year lease for new office space in Redwood City, California, with monthly rent starting at $57,400.

Soleno Therapeutics held its 2024 Annual Meeting of Stockholders, where they elected a Class I director, ratified the appointment of their accounting firm, and approved an amended equity incentive plan.

Soleno Therapeutics announced its first quarter 2024 financial results, highlighted by a significant public offering and progress on its lead drug candidate for Prader-Willi syndrome.

Soleno Therapeutics has announced the pricing of a public offering of 3,000,000 shares of its common stock at $46.00 per share, expected to raise approximately $138 million before expenses.

Soleno Therapeutics has been granted Breakthrough Therapy Designation by the FDA for its DCCR (Diazoxide Choline) extended-release tablets for the treatment of Prader-Willi Syndrome.

Gwen Melincoff, a current director of Soleno Therapeutics, will not seek re-election at the company's 2024 Annual Meeting of Stockholders.

Soleno Therapeutics announced positive results from a key clinical trial for its Prader-Willi syndrome treatment and reported a strong cash position of $169.7 million.

Soleno Therapeutics has amended its 2020 Inducement Equity Incentive Plan, adding 500,000 shares for new employee equity awards.